Exondys 51 market forecast points to faster growth in Europe

The Business Research Company says the global Exondys 51 market is set to grow through 2035 as genetic therapies, healthcare spending and rare-disease screening expand. North America led in 2025, while Europe is forecast to post the fastest growth.

Why it matters: - Exondys 51 is a targeted treatment for Duchenne muscular dystrophy, a rare and serious genetic disease with limited curative options. - The market outlook signals rising demand for exon-skipping therapies and broader investment in personalized neuromuscular care. - The report points to a larger patient-access story: more screening, more research funding and more specialty centers could expand use of the drug.

What happened: - The Business Research Company released its Exondys 51 Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Exondys 51 market is gaining attention as genetic-therapy advances and healthcare investments create new opportunities. - North America held the largest share of the global Exondys 51 market in 2025. - Europe is forecast to be the fastest-growing region over the next several years.

The details: - Exondys 51, also known as eteplirsen, is designed to treat Duchenne muscular dystrophy by promoting exon skipping of exon 51 in the dystrophin gene. - The therapy helps the body produce a shortened but functional dystrophin protein, which can slow muscle degeneration. - The report says past market growth was driven by the lack of curative DMD treatments, early reliance on supportive care, antisense research, incentives for rare-disease drugs and early regulatory approvals. - Future growth is expected to come from progress in molecular genetics, wider personalized neuromuscular care, more newborn screening programs, increased DMD research funding and more specialty neurology centers. - Major trends include more exon-skipping therapies, a wider range of targeted DMD treatments, greater use of gene-based medicines and stronger focus on slowing disease progression. - The report says increasing genetic disorders are a key driver of demand for Exondys 51. - The UK National Health Service reported in July 2024 that about 70,000 people in the UK have muscular dystrophy or related conditions. - The same NHS update said around 100 boys are diagnosed with Duchenne muscular dystrophy each year and about 2,500 people live with the condition in the UK. - The UK Office for National Statistics reported in May 2024 that healthcare spending rose 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth in the prior year. - The report says that higher healthcare spending supports clinical trials, infrastructure and access to therapies like Exondys 51. - The market analysis covers North America, Europe, Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report frames Exondys 51 as part of a broader shift toward precision medicine in rare disease care. - North America’s lead likely reflects stronger healthcare infrastructure and regulatory support. - Europe’s growth outlook suggests research investment is becoming as important as current treatment access in shaping future sales. - The emphasis on newborn screening and specialty centers points to a market that depends on diagnosis, referral pathways and long-term disease management, not just drug availability.

What’s next: - The report expects continued expansion through 2035 as genetic testing and rare-disease infrastructure improve. - More funding for DMD research and more exon-skipping products could widen the treatment pool. - The company is offering a free sample of the report and a full report download for buyers seeking deeper segment analysis and market data. - The report also highlights new 2026 features including market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspots infographics, and updated graphics and tables.

The bottom line: - Exondys 51 remains a niche rare-disease drug, but the market around it is positioned for steady growth as screening, research and targeted genetic treatments expand.